COMP <GO>

INVA vs GPCR // EV/EBITDA & P/E VALUATION

Innoviva Inc. (NASDAQ) VS. Structure Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: INVA 4 — GPCR 1

■ METRIC PARITY

LAST: $21.31 (+0.90%) • MKT CAP: $1.54B

valuation

7.6x

LAST: $21.94 (+2.14%) • MKT CAP: $1.56B

valuation

—

15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INVA VS. GPCR) EMERALD CELL = QUANTITATIVE EDGE

INSTITUTIONAL METRIC	INVA	GPCR	SPREAD (A - B)	ADVANTAGE	DEDICATED URL
Gross Profit Margin	74.80%	—	—	TIE	/gross-margins <GO>
Return on Invested Capital (ROIC)	14.70%	-19.50%	+34.20	INVA	/roic <GO>
EV/EBITDA & P/E Valuation ACTIVE	7.6x	—	—	TIE	/valuation <GO>
Free Cash Flow Yield	12.72%	-14.43%	+27.15	INVA	/fcf-yield <GO>
Operating Margin	39.80%	—	—	TIE	/operating-margins <GO>
Net Profit Margin	—	—	—	TIE	/net-margins <GO>
Revenue Growth (YoY)	14.70%	—	—	TIE	/revenue-growth <GO>
Dividend Yield & FCF Payout Safety	0.00%	0.00%	0.00	TIE	/dividend-safety <GO>
Altman Z-Score & Debt/Equity	—	—	—	TIE	/balance-sheet <GO>
Piotroski F-Score Quality	6/9	1/9	+5.00	INVA	/piotroski-score <GO>
Options Implied Move & Put/Call Skew	—	—	—	TIE	/options-implied-move <GO>
RSI-14 & 200D SMA Momentum	53.4	26.5	+26.88	INVA	/rsi-technicals <GO>
10Y Yield & FRED Macro Beta	—	—	—	TIE	/macro-sensitivity <GO>
Forward P/E Multiple	—	—	—	TIE	/forward-pe <GO>
Enterprise Scale & Market Cap	$1.54B	$1.56B	-$25.0M	GPCR	/market-cap <GO>

5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY

FISCAL YEAR	INVA REV	GPCR REV	INVA GROSS %	GPCR GROSS %	INVA FCF	GPCR FCF
FY 2025	$411.3M	$0	74.8%	—	$195.8M	-$225.8M
FY 2024	$358.7M	$0	82.6%	—	$188.4M	-$117.9M
FY 2023	$310.5M	$0	—	—	$141.1M	-$79.5M

FRED MACRO REGIME CORRELATION COMPARISON PEARSON r

INVA // BETA —

GPCR // BETA —